NCT06771180View on ClinicalTrials.gov

Dara-BCD for Rare MGRS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Monoclonal Gammopathy of Renal Significance (MGRS)
Interventions
DRUG

Dara-CyBorD

Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06771180 - Dara-BCD for Rare MGRS | Biotech Hunter | Biotech Hunter